Novel Medicaments for Anti-Retroviral Treatments

Use of a polysaccharide having the formula (1)

• wherein
• R1 represents either a hydrogen atom, a sulphate group or a phosphate group or a sulphated or phosphated glucose preferably linked by a β(1→6) type link to the saccharide structure,
• R2 represents a hydrogen atom, a sulphate group or a phosphate group, provided that R1 and R2 do not represent simultaneously a hydrogen atom,
• X and Y represent, each independently, an OH group, a glucose, a sulphated or phosphated glucose, a mannitol or a sulphated or phosphated mannitol,
• n represents an integer from 11 to 30, preferably from 20 to 30 and more preferably from 25 to 30,
• said polysaccharide having a sulphation degree greater than 2, preferably from 2.2 to 2.4, or a phosphation degree greater than 1, preferably 1.5 to 2.5, for implementing a method of treatment of retroviral diseases.

A combination product comprising an effective amount

• a polysaccharide having the formula (I) wherein R1 represents either a hydrogen atom, a sulphate group or a phosphate group or a sulphated or phosphated glucose preferably linked by a β(1→6) type linkage to the saccharide structure, R2 represents a hydrogen atom, a sulphate group or a phosphate group, X and Y each independently represent an OH group, a glucose, a sulphated or phosphated glucose, a mannitol or a sulphated or phosphated mannitol, n represents an integer from 11 to 30, preferably from 20 to 30, more preferably from 25 to 30, said polysaccharide having a sulphation degree greater than 2, preferably from 2.2 to 2.4, or a phosphation degree greater than 1, preferably from 1.5 to 2.5,
• of at least one anti-retroviral agent selected from the group comprising:
• nucleoside inhibitors of reverse transcriptase (NIRT), notably AZT, ddl, ddC, d4T, 3TC and ABC,
• the non-nucleoside inhibitors of reverse transcriptase (NNIRT), notably Viramune and Sustiva,
• the protease inhibitors, notably Agnerase and Kaletra,
• the fusion inhibitors, notably enfuvirtide (Fuzeon),
• the entry inhibitors, notably AMD-3100 and, optionally
• at least one pharmacological agent selected from the group comprising the anti-nausea agents, the anti-diarrhoea agents, the anti-hyperbilirubinemia agents, the analgesic agents, the dermatological treatment agents, the anti-nephrotoxic agents, for simultaneous, separate or stepped use over time.

Use of an effective amount of

• a polysaccharide having the formula (I) wherein R1 represents either a hydrogen atom, a sulphate group or a phosphate group or a sulphated or phosphated glucose preferably linked by a β(1→6) type linkage to the saccharide structure, R2 represents a hydrogen atom, a sulphate group or a phosphate group, X and Y each independently represent an OH group, a glucose, a sulphated or phosphated glucose, a mannitol or a sulphated or phosphated mannitol, n represents an integer from 11 to 30, preferably from 20 to 30, more preferably from 25 to 30, said polysaccharide having a sulphation degree greater than 2, preferably from 2.2 to 2.4, or a phosphation degree greater than 1, preferably from 1.5 to 2.5,
• of at least one anti-retroviral agent selected from the group comprising:
• nucleoside inhibitors of reverse transcriptase (NIRT), notably AZT, ddl, ddC, d4T, 3TC and ABC,
• the non-nucleoside inhibitors of reverse transcriptase (NNIRT), notably Viramune and Sustiva,
• the protease inhibitors, notably Agnerase and Kaletra,
• the fusion inhibitors, notably enfuvirtide (Fuzeon),
• the entry inhibitors, notably AMD-3100 and, optionally
• at least one pharmacological agent selected from the group comprising the anti-nausea agents, the anti-diarrhoea agents, the anti-hyperbilirubinemia agents, the analgesic agents, the dermatological treatment agents, the anti-nephrotoxic agents, for the manufacture of a medicament for the treatment of retroviral diseases, preferably those caused by the lentiviruses and the oncoviruses, more preferably caused by HIV, particularly by the strains of these viruses that are resistant to the already known anti-retroviral agents.

Use of an effective amount of

• a polysaccharide having the formula (I) wherein R1 represents either a hydrogen atom, a sulphate group or a phosphate group or a sulphated or phosphated glucose preferably linked by a β(1→6) type linkage to the saccharide structure, R2 represents a hydrogen atom, a sulphate group or a phosphate group, X and Y each independently represent an OH group, a glucose, a sulphated or phosphated glucose, a mannitol or a sulphated or phosphated mannitol, n represents an integer from 11 to 30, preferably from 20 to 30, more preferably from 25 to 30, said polysaccharide having a sulphation degree greater than 2, preferably from 2.2 to 2.4, or a phosphation degree greater than 1, preferably from 1.5 to 2.5,
• of at least one anti-retroviral agent selected from the group comprising:
• nucleoside inhibitors of reverse transcriptase (NIRT), notably AZT, ddl, ddC, d4T, 3TC and ABC,
• the non-nucleoside inhibitors of reverse transcriptase (NNIRT), notably Viramune and Sustiva,
• the protease inhibitors, notably Agnerase and Kaletra,
• the fusion inhibitors, notably enfuvirtide (Fuzeon),
• the entry inhibitors, notably AMD-3100 and, optionally
• at least one pharmacological agent selected from the group comprising the anti-nausea agents, the anti-diarrhoea agents, the anti-hyperbilirubinemia agents, the analgesic agents, the dermatological treatment agents, the anti-nephrotoxic agents, for the implementation of a method of treatment of retroviral diseases, preferably those caused by the lentiviruses and the oncoviruses, more preferably caused by HIV, particularly by the strains of these viruses that are resistant to the already known anti-retroviral agents.